Acura Pharmaceuticals Inc
OTC:ACUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acura Pharmaceuticals Inc
Research & Development
Acura Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acura Pharmaceuticals Inc
OTC:ACUR
|
Research & Development
-$1.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Acura Pharmaceuticals Inc
Glance View
Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.
See Also
What is Acura Pharmaceuticals Inc's Research & Development?
Research & Development
-1.5m
USD
Based on the financial report for Dec 31, 2021, Acura Pharmaceuticals Inc's Research & Development amounts to -1.5m USD.
What is Acura Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
9%
Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Acura Pharmaceuticals Inc have been 5% over the past three years , 18% over the past five years , and 9% over the past ten years .
